SNMMI Image of the Year Is the Endocyte 177 Lu PSMA-617?
Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. Positron emission tomography (PET) scans showing very positive results obtained in cancer patients after treatment with the radionuclide lutetium-177 (177Lu) PSMA-617 prostate cancer therapy were selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) as the SNMMI Image of the year. ABX (a CIL subsidiary) licensed this therapy last year to Endocyte. Read more at http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29483
Articles
- Lysine Propionylation Boosts Proteome Sequence Coverage and Enables a “Silent SILAC” Labeling Strategy for Relative Protein Quantification
- 13C-Labeled Yeast as Internal Standard for LC-MS/MS and LC High Resolution MS Based Amino Acid Quantification in Human Plasma
- Glutamine-Derived 2-Hydroxyglutarate Is Associated with Disease Progression in Plasma Cell Malignancies
- Hepatic Ketogenic Insufficiency Reprograms Hepatic Glycogen Metabolism and the Lipidome
- A Targeted Metabolomics Approach for Clinical Diagnosis of Inborn Errors of Metabolism
- A Guide to 13C Metabolic Flux Analysis for the Cancer Biologist
- SNMMI Image of the Year Is the Endocyte 177 Lu PSMA-617?
